Plasma GLP-1 concentration peaked at 15 minutes post glucose load, and insulin peaked at 30 minutes, suggesting GLP-1 potentiated or triggered insulin secretion
Key risks include hypoglycaemic agents like insulin and gliclazide, risking potentially life-threatening hypoglycaemia, and inappropriate antihypertensive treatments increasing falls risk
Overall, sustained innovation, favorable reimbursement, and rising health awareness are expected to reinforce long-term market growth
Br J Pharmacol 179(4):557570 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018a) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy
The use of technology in healthcare, such as dosage calculators, reflects a broader trend towards data-driven medicine, where decisions are informed by evidence and tailored to individual circumstances